Literature DB >> 14637384

Resiniferatoxin-induced loss of plasma membrane in vanilloid receptor expressing cells.

Robert M Caudle1, Laszlo Karai, Narasaiah Mena, Brian Y Cooper, Andrew J Mannes, Federico M Perez, Michael J Iadarola, Zoltan Olah.   

Abstract

Resiniferatoxin (RTX), a potent analog of capsaicin, was evaluated electrophysiologically in dorsal root ganglion (DRG) cells and cell lines ectopically expressing the vanilloid receptor type 1 (VR1) to determine if cell phenotype influenced RTXs neurotoxic properties. Furthermore, capsaicin and heat activation of VR1 were evaluated in these cells to determine if cellular damage was unique to RTX activation of the receptors. RTX application to DRG cells identified as type 1, 2 or 5, cell types known to express VR1, induced large inward currents. RTX did not induce currents in DRG cells that do not express the receptor (type 4 cells). In cell lines ectopically expressing VR1, RTX-induced similar currents. RTX produced no effect in non-transfected cells. After exposure to RTX both DRG cells and transfected cells failed to respond to subsequent applications of the agonist. In addition, whole cell capacitance was reduced up to 70%. The decrease in capacitance was associated with the loss of plasma membrane, as determined by confocal microscopy. Cell phenotype, other than VR1 expression, did not influence the response to RTX. Interestingly, capsaicin and heat activation of vanilloid receptors also decreased cell capacitance, but the loss of membrane was not as great as with RTX and responses to these stimuli were not lost after the initial exposure. The loss of cell membrane required elevated intracellular levels of Ca2+. From these data it was concluded that the loss of cell membrane was dependent on the presence of both VR1 and intracellular Ca2+ accumulation, but not on cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14637384     DOI: 10.1016/S0161-813X(03)00146-3

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  20 in total

Review 1.  TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.

Authors:  António Avelino; Francisco Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-24       Impact factor: 3.000

2.  Structure-activity relationships of 1,4-dihydropyridines that act as enhancers of the vanilloid receptor 1 (TRPV1).

Authors:  Eun Joo Roh; Jason M Keller; Zoltan Olah; Michael J Iadarola; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2008-08-26       Impact factor: 3.641

Review 3.  The vanilloid agonist resiniferatoxin for interventional-based pain control.

Authors:  Michael J Iadarola; Andrew J Mannes
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

4.  TRPV1-Targeted Drugs in Development for Human Pain Conditions.

Authors:  Mircea Iftinca; Manon Defaye; Christophe Altier
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

5.  Ca2+ and calpain mediate capsaicin-induced ablation of axonal terminals expressing transient receptor potential vanilloid 1.

Authors:  Sheng Wang; Sen Wang; Jamila Asgar; John Joseph; Jin Y Ro; Feng Wei; James N Campbell; Man-Kyo Chung
Journal:  J Biol Chem       Date:  2017-03-30       Impact factor: 5.157

6.  Agonist- and Ca2+-dependent desensitization of TRPV1 channel targets the receptor to lysosomes for degradation.

Authors:  Lucía Sanz-Salvador; Amparo Andrés-Borderia; Antonio Ferrer-Montiel; Rosa Planells-Cases
Journal:  J Biol Chem       Date:  2012-04-06       Impact factor: 5.157

7.  Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1.

Authors:  Yi-Chen Lee; Shui-Chin Lu; Yu-Lin Hsieh
Journal:  J Vis Exp       Date:  2018-02-13       Impact factor: 1.355

Review 8.  Corneal pain and experimental model development.

Authors:  Tina B McKay; Yashar Seyed-Razavi; Chiara E Ghezzi; Gabriela Dieckmann; Thomas J F Nieland; Dana M Cairns; Rachel E Pollard; Pedram Hamrah; David L Kaplan
Journal:  Prog Retin Eye Res       Date:  2018-11-16       Impact factor: 21.198

9.  Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control.

Authors:  Laszlo Karai; Dorothy C Brown; Andrew J Mannes; Stephen T Connelly; Jacob Brown; Michael Gandal; Ofer M Wellisch; John K Neubert; Zoltan Olah; Michael J Iadarola
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

10.  Prolonged analgesic response of cornea to topical resiniferatoxin, a potent TRPV1 agonist.

Authors:  Brian D Bates; Kendall Mitchell; Jason M Keller; Chi-Chao Chan; William D Swaim; Ruth Yaskovich; Andrew J Mannes; Michael J Iadarola
Journal:  Pain       Date:  2010-04-18       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.